Erdheim-Chester disease is a rare non-Langerhans histiocytosis with multisystem involvement. To date, there is no standard treatment for this disorder, and over half of the patients succumb within three years. Because interferon-alpha promotes the terminal differentiation of histiocytes and dendritic cells, we hypothesized that this molecule would be a useful therapy for Erdheim-Chester disease. We therefore treated three patients with advanced disease with interferon-alpha at a starting dose of 3 to 6 x10 6 units, which was later reduced, during maintenance, to 1 x10 6 units s.c.
Introduction
In 1930, William Chester described the first two cases of "lipoid granulomatosis", later renamed Erdheim-Chester disease [1] . This illness represents a rare non-Langerhans histiocytosis with particular tropism for connective and adipose tissues. Clinical features range from a focal asymptomatic process to a multisystem, rapidly fatal, infiltrative disease with a total of about 250 cases described in the literature [2] [3] [4] [5] [6] [7] . Typically it affects adults of both genders, with symmetric osteosclerosis of the long bones sparing the epiphyses [2, 3] . The histiocytes mainly infiltrate bones, pituitary, orbit, retroperitoneum and central nervous system [2] [3] [4] [5] . The pathology is characterized by large, foamy or eosinophilic cytoplasm lipid-laden CD68-positive, CD1a and S100 negative histiocytes lacking any Birbeck granules; and the pathognomonic Touton-like giant cells, which are multinucleated cells with the nuclei organized in a wreath-like ring and a xanthomatous cytoplasm [4, 6, 8] .
There is no standard treatment for Erdheim-Chester disease. Unfortunately, about 60% of patients succumb to their disease within 32 months of presentation [2] .
Of interest, researchers reported that interferon-results in terminal differentiation of histiocytes and dendritic cells [9, 10] . We therefore administered interferon-to three patients with Erdheim-Chester disease. This treatment resulted in durable responses, with the longest ongoing at four years. Chester disease ( Figure 1C ).
The patient was treated with 3x10 6 units of s.c. interferon-three times per week. Within one month he was able to taper off corticosteroids, and showed recovery of his visual acuity and visual fields. Repeat MRI of the orbits three months later showed substantial improvement [11] . The patient 's persistent fatigue resolved with a reduction of the interferon-dose down to one million units three times per week.
Four years later, the patient remains asymptomatic on this maintenance dose. His MRI shows further decrease in his retro-orbital mass size and its inflammatory activity Figure 1B) . His diabetes insipidus has also improved with a 87.5% reduction of his daily desmopressin dose.
Patient 2:
A 58-year-old man was evaluated for ongoing leg pain, treated diabetes For
Results and Discussion:
Erdheim-Chester disease is a rare non-Langerhans histiocytosis of unknown etiology. The outcome of patients with Erdheim-Chester disease is worse than that for Langerhans cell histiocytosis with 59% of patients in the former group dead after a mean follow up of 32 months [2] , whereas only 9% of patients with the latter disorder have succumbed after a median follow up of four years [12] .
Numerous treatments have been attempted for this disease [2, 6, 13, 14] .
Corticosteroids are the traditional first-line treatment and are used to control symptoms, but generally are either ineffective or only transiently effective [2, 6] .
Bisphosphonates are efficient in treating osteolytic lesions in Langerhans cell histiocytosis but have only partial or temporary success in the management of bone involvement in Erdheim-Chester disease [15] . Chemotherapy can induce transient partial responses, but is often ineffective [2, 16] . Cladribine has been used successfully in adult Langerhans histiocytosis, but its application in Erdheim-Chester disease is limited to two patients, one of whom responded [16, 17] . Radiation, methotrexate, cyclosporine and azathioprine have not yielded sustained clinical response [3, 18, 19, 20] .
We describe the successful treatment of three patients suffering from ErdheimChester disease with interferon-. The initial therapeutic dose of 3 to 6x10 6 Erdheim-Chester disease is a rare and difficult-to-treat disease. All three of our patients with this disorder achieved a long-lasting response (3+, 3.5 and 4.5+ years) while receiving interferon-. Our observations suggest that this well-tolerated treatment warrants further application and investigation in this disorder.
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